← Back to all trials
Completed
NCT02905578
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
Conditions: Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 40
Sponsor: University of Iowa
Location: Holden Comprehensive Cancer Center Iowa City Iowa
Summary
This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate in addition to the standard treatment).
Eligibility Criteria
Inclusion Criteria:
* Pathologic diagnosis (cell samples, biopsy, brushing, surgical sample) of adenocarcinoma of the pancreas. Cancer from the Ampullae of Vater is also eligible. The tissue sample can be from a metastatic location, like a lymph node.
* Metastatic or node positive disease
* One cancer site, that did not receive radiation therapy, that is at least 1 cm in size when looking at it by CT scan (CAT scan)
* Recommended to receive gemcitabine and nab-paclitaxel
* Failed initial therapy or be ineligible for definitive curative therapy (e.g., surgical excision, radiation therapy)
* A platelet count of at least 100,000 cells per mL
* A creatinine level of less than 1 1/2 times the upper limit of normal for the local lab test, or, a creatinine clearance of at least 60 mL/(min\*1.73m2)
* Not pregnant
* Commit to using birth control during the study (all participants)
Exclusion Criteria:
* Prior chemotherapy to treat the metastatic disease
* Other therapy (including radiation) within the past 4 weeks
* Side effects from prior therapies that are still deemed moderate to severe by a physician
* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
* Patients actively receiving insulin or who are currently recommended to receive insulin by a doctor
* Patients requiring daily finger-stick blood glucose measurements
* Patients who are on the following drugs and cannot have a substitution (or who decline the substitution):
* warfarin
* flecainide
* methadone
* amphetamines
* quinidine
* chlorpropamide
* An active cancer, other than the pancreatic cancer, that requires treatment.
* Enrolled in another therapeutic clinical trial
* Uncontrolled, intercurrent illness
* HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy
* Women who are nursing
Source: ClinicalTrials.gov (NCT02905578). StuddyBuddy aggregates publicly available trial information.